Trial
NCT05733351
Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Emory University
Collaborators
National Cancer Institute (NCI); Xencor, Inc.
Condition
Castration-Sensitive Prostate Carcinoma
Intervention
Abiraterone
Why stopped
To review the safety data.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-15